First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).

Lauren C. Harshman(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Sumanta K. Pal(City of Hope), Srinivas K. Tantravahi(University of Utah), Frede Donskov(Aarhus University Hospital), Scott North, Jennifer J. Knox(National Cancer Center), Nils Kroeger(Universitätsmedizin Greifswald), Ulka N. Vaishampayan(University of Michigan), Lori Wood(Dalhousie University), Takeshi Yuasa(Japanese Foundation For Cancer Research), Sandy Srinivas(Stanford University), Mary J. MacKenzie(Cancer Care Ontario), Sun Young Rha(Yonsei University), Daniel Yick Chin Heng(University of Calgary), Brian I. Rini(Vanderbilt University Medical Center)
Journal of Clinical Oncology
May 20, 2013
10.1200/jco.2013.31.15_suppl.e15518
Cited by 2

Related Papers

The Immune Landscape of Cancer
|Immunity|2018|6.3k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k